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Abstract The primary objective of this study was to examine
the association between depression, anxiety symptoms, and
glycemic control in Malaysian women with type 2 diabetes
mellitus (T2DM). Another objective was to examine the as-
sociation between glycemic control and mental status, mea-
sured by mental composite score (MCS). This study was
conducted on 611 randomly sampled Malaysian women with
T2DM who were treated as outpatients at medication therapy
adherence clinics (MTAC). The Delusions-Symptoms-States
Inventory: State of Anxiety and Depression (DSSI/SAD) and
Center for Epidemiologic Studies Depression Scale 10 (CES-
D 10) were used. Five most recent readings of hemoglobin
A1c (HbA1c), fasting, and random glucose levels were re-
corded. Regression analysis was used to correlate glycemic
control with depression, anxiety symptoms, and MCS, while
considering potential confounders. For depression symptoms,
an increase of one category was associated with a small
average HbA1c increase of 0.10 % (95 % CI −0.38, 0.68),
whereas for anxiety symptoms, there was a small decrease in
average HbA1c of 0.44 % (95 % CI −1.17, 0.28); both were
not significant. Very poorly controlled HbA1c was not signif-
icantly associated with symptoms of depression (OR 1.43,
95 % CI 0.45–4.55) or anxiety (OR 0.47, 95 % CI 0.15–
1.49). MCS was found to have a strong inverse correlation
with HbA1c. That is, women who reported poor MCS had a
significantly higher, and therefore very poorly controlled,
HbA1c (OR 1.70, 95 % CI 1.01–2.88). The presence of
depression and anxiety symptoms was not significantly asso-
ciated with glycemic control in women with T2DM,
supporting the hypothesis that argues against the existence
of a link between depression, anxiety, and glycemic control.
Keywords Mental health . Depression . Anxiety . Type 2
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Introduction
People with diabetes mellitus (DM) experience a number of
complications during the course of the disease, including
psychological problems. Depression and anxiety are the two
most common comorbid conditions associated with DM [1].
Comorbid depression or anxiety together with DM may result
in poor metabolic control, higher complication rates, poorer
quality of life (QoL), increased management costs, disability,
and mortality rates [2–4]. It has been estimated that depressive
disorders are higher among women with or without diabetes
than among men; globally, depressive disorders in women
were the fourth leading cause of disease burden and the
seventh leading cause in men [2–4]. Studies from developed
countries reported higher prevalence of depression in women
compared to men [3, 5]. Although not many studies have been
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conducted in developing countries, a higher prevalence of
depression and anxiety symptoms among women has been
reported [6, 7]. Women with DM also exhibit poorer diabetes
self-care, glycemic control, and QoL than men with DM,
which are further exacerbated by depression [8].
Glycemic control is one of the top priorities in the man-
agement of people with DM in order to reduce the macro- and
micro-vascular complications [9]. Depression has been found
to affect glycemic control as well as macro-vascular and
micro-vascular complications [9–11], and there is substantial
evidence that comorbid depression among individuals with
DM is associated with poor DM outcomes such as poor
glycemic control [9, 12].
Significant controversy exists over whether or not depres-
sion and anxiety in patients with DM is associated with poorer
glycemic control, with some studies reporting moderate to
strong associations [10, 13–15] between depression symp-
toms and hemoglobin A1c (HbA1c), while others have found
no association [16–18]. Recent studies suggest that anxiety
disorders may also be associated with less favorable glycemic
control among adults with DM [19–21]. However, glycemic
control as a risk factor was associated only with higher anxiety
scores [22]. Prevalence of moderate to severe depression was
found to be significantly associated with poor glycemic con-
trol in men but not in women [19, 23], and cross-sectional
studies have found a significant positive correlation between
depression symptoms and HbA1c in patients with type 1
diabetes but no significant correlation in patients with type 2
diabetes mellitus (T2DM) [24, 25]. The evidence gives rise to
the hypothesis that depression and anxiety affect glycemic
control in men and those with type 1 DM but not women
and patients with T2DM. In order to test this hypothesis in a
developing country, we conducted a study to examine the
association between depression, anxiety symptoms, and gly-
cemic control in Malaysian women with T2DM.
Methods
Study design and participants
Six hundred and eleven Malaysian women with a known
diagnosis of T2DM for at least 1 year, who were treated as
outpatients at medication therapy adherence clinics (MTAC)
at PutraJaya Hospital in PutraJaya, and Tuanku Jaa’far Hos-
pital and Seremban Health Clinic in Negeri Sembilan, were
invited to participate in this study. Face-to-face interviews
were conducted at the outpatient clinics, using self-
administered questionnaires. The study was conducted ac-
cording to the principles expressed in the Declaration of
Helsinki and was approved by the School of Pharmacy Ethics
Committee at The University of Queensland, Australia (Ref.
No. 2011/14), and the International Medical University
Research and Ethics Committee (Project ID No: B01/09-Res
(04) 2012).
Women were categorized as having T2DM if they were
attending MTAC for the management of T2DM. Every sec-
ond woman with diabetes on the respective patients’ list at the
clinic sites was invited to participate; verbal or written consent
was obtained from participants who met the inclusion criteria.
The data were collected on women aged 35 and above. Infor-
mation was confirmed by accessing patients’medical records.
The presence of T2DM was identified according to two
criteria: A fasting plasma glucose (FPG) greater than or equal
to 7.0 mmol/l and random plasma glucose (RPG) greater than
or equal to 11.1 mmol/l. Women diagnosed with T1DM were
excluded.
Measurement of depression and anxiety symptoms
Center for Epidemiologic Studies Depression Scale 10 (CES-
D 10), a brief self-report screening tool for depressive symp-
toms derived from the validated 20-item CES-D 20 [26], was
used to assess depression symptoms. It has been shown to
have reliability and validity comparable to the standard 20-
item CES-D instrument and is considered a good instrument
for screening depression in patients with T2DM [27]. The
CES-D 10 uses a zero-to-three response scale, with total
symptom severity scores ranging from 0 (no depression) to
30 (severe depression) [28]. Participants in this study were
categorized as depressed if they scored 11 or more; this is a
commonly used cutoff point for CES-D [26].
The anxiety symptoms were assessed using the Delusions-
Symptoms-States Inventory: State of Anxiety and Depression
(DSSI/SAD). It contains 14 symptoms, 7 for depression and 7
for anxiety. The DSSI was developed for use with community
samples and has been validated against clinical samples with
diagnosed mental illness [29–31], and was also found to
correlate well, and shares items with, other established symp-
toms scales such as the Edinburgh Postnatal Depression Scale
(EPDS) and the Hospital Anxiety/Depression Scale (HADS)
[32]. Participants in this study were classified as anxious when
they reported four or more symptoms.
DSSI/SAD is an instrument used to evaluate anxiety and
depression symptoms but has not yet been validated for use
among people with diabetes [29]. Therefore, we validated the
DSSI instrument. Internal consistencywas 0.86 for the anxiety
and 0.90 for depression subscales, and 0.93 for the full scale of
DSSI/SAD. Principal component analysis revealed a bi-
factorial model. Correlation analysis showed a significant
negative correlation between DSSI-Anxiety and the mental
composite score (MCS) scale of Short Form 12 of the Medical
Outcomes Study (SF-12; r=−0.404, p=0.001); thus, as anxi-
ety symptoms decreased (DSSI), the MCS increased, indicat-
ing lower mental health-related limitations. We found signif-
icant variations in the DSSI/SAD domain scores that could be
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explained by CES-D (DSSI-Anxiety 55 %, DSSI-Depression
46 %) and SF-36 MCS (DSSI-Anxiety 66 %, DSSI-
Depression 56 %) suggesting that the DSSI/SAD can be used
for measuring depression and anxiety symptoms in people
with diabetes.
Mental health status by mental composite score (MCS)
We also measured overall mental health functioning using
MCS of the SF-12. SF-12 is a multipurpose survey instrument
comprising 12 questions, developed as a legitimate alternative
to the SF-36. The two summary scales, MCS and the Physical
Component Summary (PCS), provide an insight into mental
and physical health as well as disability level [33]. MCS
examining the impact of health on mental health function
was calculated using the method described by Ware et al.
[34]. The MCS ranged from 0 to 100; “0” implies poor mental
health and “100” implies goodmental health. Themedian split
method was used to categorize participants where scores less
than the median indicate poor MCS.
Assessment of glycemic control
Five most recent blood glucose readings were collected from
patients’ medical records. Mean and median values were
calculated and used for all comparisons. The monitoring of
hemoglobin A1c (HbA1c) is considered the gold standard for
glycemic control. The general HbA1c target in people with
T2DM is ≤7 %, and adjustment to diabetes treatment should
be considered when HbA1c is above this level [35], although
other guidelines suggest 6.5 % or less as the treatment goal,
which is closer to the normal healthy value [36]. The HbA1c,
fasting blood glucose (FBG), and random blood glucose
(RBG) values were used as both continuous and categorical
outcomes. We used >7 % HbA1c value as the cutoff point to
define poor glycemic control. The HbA1c was also catego-
rized based on quartile values: good controlled, moderately
controlled, poorly controlled, and very poorly controlled
HbA1c.
For fasting and random blood glucose, we used the Na-
tional Health and Medical Research Council (NHMRC) clas-
sification for people with T2DM, namely normal, moderate,
and high levels [37]. A fasting value between 4 and 6 mmol/l
was normal, between 6.1 and 6.9 mmol/l was moderate, and
anything above 7 mmol/l was high [37]. For non-fasting or
random blood glucose, a normal value was between 4 and
7.7 mmol/l, between 7.8 and 10.9 mmol/l was moderate, and
anything above 11 mmol/l was high [37].
Assessment of covariates
Potential confounders and risk factors were identified on the
basis of their association with outcomes and a priori
knowledge [11, 23, 38]. Socio-demographic information in-
cluded age, ethnicity, education, occupation, monthly income,
alcohol consumption, and cigarette smoking (non-smokers,
past smokers, and current smokers). These were collected
from participants. Clinical and physical parameters such as
comorbidities or medical conditions other than T2DM and
height (m) and weight (kg) measurements were obtained from
participants’medical records. Body mass index (BMI, kg/m2)
was then calculated to categorize participants based on the
WHO criteria [39]. For physical health, the Short Form 12 of
the Medical Outcomes Study (SF-12) was used, with lower
scores indicating poor physical health. The PCS scores were
calculated using the scores of the questions, ranging from 0 to
100, with lower scores indicating greater physical limitation
[33]. The median split method was used to categorize partic-
ipants where scores less than median indicate poor PCS. The
self-reported information on level of physical activity (not at
all, one to two times a week, three or more times a week), and
sleep problems (Nil, acute and chronic), were collected from
participants.
Statistical analysis
The data were analyzed using the Statistical Package for
the Social Sciences (SPSS)® version 20 and Stata IC®
version 12, with a significance level of ≤0.05. Descrip-
tive statistics were used to calculate percentages, fre-
quencies, means, and standard deviations. The relation-
ship between variables for categorical data was per-
formed using the χ2 (Chi-Sq). Fisher exact test was
applied in cases where sample size was small. Similarly,
on occasions where we had less than five readings per
cell for Chi-Sq, likelihood ratio test was applied. Com-
parisons between groups with normal distribution were
performed using the Student’s t test. Pearson’s correla-
tion test was used to verify the existence of a correla-
tion between instruments’ mean scores or other values.
Therefore, a series of multiple linear, logistic, and
multinomial regression models (see footnotes of Ta-
bles 3, 4, 5, and 6) was used to determine the associ-
ation of mean blood glucose levels with depression and
anxiety symptoms assessed as continuous and categori-
cal outcomes. The effects were adjusted for demograph-
ic, lifestyle, and clinical factors [11, 23, 38]. For logis-
tic regression, we used the median split method to
categorize the variables into binary groups. These binary
groups include number of pregnancies, age at last preg-
nancy, and PCS. For potential confounding, the unad-
justed associations of depression and anxiety symptoms
with glycemic control were compared with the adjusted
associations, with confounding confirmed when the un-
adjusted effect size and adjusted effect size estimates
differed.
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Results
Socio-demographic characteristics and glycemic control
The median ages of the 611 participating women at the time of
this study and at diabetes diagnosis were 58 and 48 years,
respectively. The majority were aged between 45 and 64 years
(67 %), were married (82 %), were of Malay ethnicity (38 %),
had completed only primary education (76.3 %), and were
earning less than 3500 Ringgit Malaysia monthly (1 RM=3.1
US$). Regarding HbA1c levels, there were higher levels
among younger women aged 35 to 44 (8.14±1.47) and 45
to 54 years (8.37±1.98) than older women (7.43±1.51).
Women of Indian ethnicity had higher levels of HbA1c
(8.73±1.98) compared to other ethnic groups. The median
values of HbA1c, FBG, and RBG were 7.77 % (N=611),
7.65 mmol/l (N=352), and 9.80 mmol/l (N=314),
respectively.
Anxiety and depression symptoms and glycemic control
Depression (8.7 %) and anxiety (9.0 %) symptoms were not
commonly reported by participants in this study. Women with
anxiety had slightly higher FBG (8.54 versus 8.34) and RBG
(11.10 versus 9.87) levels compared to women without anx-
iety symptoms. Unlike women with anxiety, women with
depression symptoms had slightly higher HbA1c (8.24 versus
8.10) compared to women with no depression (Table 1). Cor-
relation analysis shows a weak correlation between HbA1c
and anxiety (inverse) and HbA1c and depression (positive)
symptoms.
The univariate analysis shows that for an increase of one
category of depression symptoms, there were small increases
in HbA1c (0.15 %, 95 % CI −0.38–0.68), FBG (0.33 mmol/l,
95 % CI −0.77–1.42), and RBG (1.02 mmol/l, 95 % CI
−0.20–2.25). The effect estimates were reduced after adjust-
ments for the effect of confounders (Table 2). In case of
anxiety symptoms, HbA1c decreased by a small amount.
Very poorly controlled HbA1c was not significantly asso-
ciated with increased odds of depression (OR 1.43, 95 % CI
0.45–4.55) and anxiety (OR 0.47, 95 % CI 0.15–1.49) symp-
toms; similarly, neither weremoderately and poorly controlled
HbA1c (Table 3). The high FBG range was not significantly
associated with increased odds of anxiety (3.38, 95 % CI
0.67–17.11) and depression (1.47, 95 % CI 0.41–5.26) symp-
toms (Table 4). Similarly, the expected risk remaining in the
high RBG range was higher for women with anxiety and
depression symptoms, but this was not significant (Table 5).
Mental health function and glycemic control
Almost half of the participating women were found to have
poormental health functional status, as measured byMCS. On
average, women with poor MCS had higher HbA1c, FBG,
and RBG compared to women with good MCS (Table 1).
Correlation analysis shows a strong inverse correlation be-
tween HbA1c and MCS.
A 1-unit score increase in the MCS was associated with
0.47 % (0.17, 0.77), 0.70 mmol/l (0.10, −1.31), and
0.11 mmol/l (−0.58, 0.79) HbA1c, FBG, and RBG levels,
respectively. We found very little confounding of MCS, since
there was little difference between the univariate analysis
coefficients and the adjusted coefficients (Table 2). Poor
MCS were significantly associated with very poorly con-
trolled HbA1c (OR 1.93, 95 % CI 1.22–3.03) and remained
significant after adjustments for confounders (OR 1.70, 95 %
CI 1.01–2.88); however, neither moderately nor poorly con-
trolled HbA1c was observed compared to women with normal
level (Table 3).
Discussion
This was the first study to investigate the association between
depression, anxiety symptoms, and glycemic control among
Malaysian women with T2DM. We did not find strong asso-
ciations between depression and glycemic control or between
anxiety and glycemic control. However, women with comor-
bid depression and anxiety symptoms had higher mean blood
glucose values compared to those without depression and/or
anxiety symptoms. In our study, fewer than 10 % of women
with T2DM exhibited depression and anxiety symptoms. In
contrast, almost half of the women reported poor mental
functional status, as measured by MCS, indicating the oppo-
site trend. Almost two thirds of the women (65.6 %) had
HbA1c values greater than 7 % and more than a quarter of
them were above 9 % indicating poor glycemic control. This
reflects the trend reported by the American Diabetes Associ-
ation (ADA)which suggest that only one of every two patients
with diabetes has glycosylated HbA1c levels <8.0%, and very
few patients sustain HbA1c levels <7.0 % [40].
Depression and anxiety were more common among people
with poor glycemic control; however, the underlying mecha-
nisms are not well elucidated, with some studies reporting that
people with poor glycemic control are more likely to become
depressed or anxious [4, 10, 13–15, 19–21], while we found
that only people with very poorly controlled glucose levels, as
measured by MCS, were associated with poor mental health
status. Our study found differences between people with poor
glycemic control and normal glycemic level in overall mental
health functioning but not specifically in mental health or
vitality domains of MCS. The exact explanation for the asso-
ciation we observed is unclear: glycemic control may affect
emotional and social function, persons with better emotional
function may be more likely to be prevented from negative
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and positive effects of poor glycemic control, or glycemic
control may be linked with other confounding variables that
affect mental health function.
Our study shows that for an increase of one category of
symptoms of depression, HbA1c increased, on average, by
only a small amount of 0.10 %. A similar increment was
reported in a longitudinal study of people with T2DM who
showed, over a 4-year period, HbA1c values which were, on
average, 0.13 % higher in people who had depression [12].
Previous studies have come to different conclusions about the
association of depression symptoms and glycemic control;
some reported a significant relationship between poorer gly-
cemic control and depressive symptoms [14, 41] while others
found an insignificant or weak association between glycemic
control and depressive symptoms [18, 38, 42]. However, a
meta-analysis reported a significant association [9], and ran-
domized clinical trials of therapies for depression demonstrat-
ed improvement in depressive symptoms corresponding with
improvements in glycemic control [43, 44], and vice versa
[14].
Table 1 Mental health status of women with T2DM, by means and standard errors of HbA1c, fasting, and random blood glucose levels
Variables HbA1c (N=611) Fasting BG (N=352) Random BG (N=314)
N Mean SE 95 % CI N Mean SE 95 % CI N Mean SE 95 % CI
Depression
No depression 558 8.10 0.08 7.94–8.25 321 8.32 0.16 8.00–8.65 288 9.88 0.18 9.53–10.23
Depression symptoms 53 8.24 0.27 7.70–8.78 31 8.65 0.61 7.40–9.90 26 10.91 0.67 9.53–12.28
Anxiety
No anxiety 558 8.11 0.08 7.95–8.27 321 8.34 0.16 8.01–8.66 289 9.87 0.18 9.53–10.22
Anxiety symptoms 53 8.06 0.25 7.56–8.57 31 8.54 0.60 7.31–9.76 25 11.10 0.71 9.60–12.54
Mental health—MCS
Good MCS 323 7.88 0.10 7.69–8.07 173 8.00 0.20 7.60–8.40 177 9.92 0.22 9.49–10.35
Poor MCS 288 8.35 0.12 8.12–8.59 179 8.70 0.24 8.22–9.17 137 10.04 0.28 9.47–10.59
BG blood glucose, SE standard error, MCS mental composite score
Table 2 The associations between symptoms of depression and HbA1c, anxiety and HbA1c (%), and FBG and RBG (mmol/l)
Variables Depression symptoms Anxiety symptoms Mental health—MCS







8.10 (7.93, 8.25) 0.15 (−0.38, 0.68) 8.11 (7.95, −8.27) −0.05 (−0.58, 0.49) 7.88 (7.68, 8.10) 0.47 (0.17, 0.77)a
Adjusted estimate
(95 % CI)
8.81 (7.67, 9.94) 0.10 (−0.63, 0.81) 8.81 (7.67,9.94) −0.44 (−1.17, 0.28) 8.39 (7.26, 9.52) 0.46 (0.12, −0.80)




8.32 (8.00, 8.65) 0.33 (−0.77, 1.42) 8.34 (8.01, 8.66) 0.20 (−0.90, 1.30) 8.00 (7.56, 8.44) 0.70 (0.10, −1.31)
Adjusted estimate
(95 % CI)
11.82 (9.39, 14.25) −0.10 (−1.53, 1.33) 11.82 (9.39, 14.25) −0.03 (−1.49, 1.44) 11.37 (8.90, 13.86) 0.44 (−0.33, 1.21)




9.88 (9.53, 10.24) 1.02 (−0.20, 2.25) 9.87 (9.52, 10.23) 1.19 (−0.05, 2.44) 9.92 (9.47, 10.38) 0.11 (−0.58, 0.79)
Adjusted estimate
(95 % CI)
10.75 (8.13, 13.37) 0.41 (−1.55, 2.36) 10.75 (8.13, 13.37) 0.13 (−1.86, 2.12) 10.75 (8.19, 13.32) −0.02 (−0.81, 0.77)
Approach used was linear regression. Depression and anxiety symptoms adjusted for depression or anxiety, age, comorbidities, physical activity, BMI,
physical health, and sleep problems
BG blood glucose, MCS mental composite score
a Statistically significant
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Although our data found no significant association be-
tween anxiety and HbA1c, HbA1c values were, on average,
0.44 % lower in those with anxiety symptoms. In contrast to
previous studies which suggest that anxiety disorders are
associated with less favorable glycemic control among adults
with DM [19–21], our data did not show such a relationship.
Interestingly, insignificant correlations of HbA1c with depres-
sion and anxiety symptoms also indicated a weak link be-
tween the two. Contrary to this, a strong inverse correlation
between HbA1c and MCS was found, suggesting that women
who score high on MCS scale appear to have lower HbA1c
level than women who score low on MCS. A 1-unit score
increase in the MCS was associated with 0.47 % (−0.17,
−0.77), 0.70 mmol/l (0.10, −1.31), and 0.11 mmol/l (−0.58,
0.79) for HbA1c, FBG, and RBG levels, respectively. The
adjusted effect of MCS on HbA1c was almost unchanged
(reduced by only 1 %), suggesting no—or very little—con-
founding. Despite strong inverse correlations of MCS with
DSSI and CES-D 10, only MCS reflected significant changes
in glycemic control in this study. MCS might have captured
the distress associated with diabetes and is reflected in the
correlation between MCS and glycemic control.
Table 3 Odds ratio (95 % CI) of poor glycemic control (HbA1c >7 %) according to depression and anxiety symptoms (N=611)
Items Depression symptoms Anxiety symptoms Mental health—MCS
No (referent) Yes No (referent) Yes Good MCS (referent) Poor MCS
HbA1c—binary outcome
Normal level, N (%) (referent) 195 (31.9) 16 (2.6) 193 (31.6) 18 (2.9) 126 (20.6) 85 (13.9)
Poor level, N (%) 363 (59.4) 37 (6.1) 365 (59.7) 35 (5.7) 197 (32.2) 203 (33.2)
Unadjusted odds 1.0 0.81 (0.44–1.48) 1.0 0.97 (0.54–1.76) 1.0 0.65 (0.47–0.92)a
Adjusted odds 1.0 0.82 (0.35–1.95) 1.0 1.36 (0.58–3.21) 1.0 0.71 (0.46–1.05)
HbA1c—quartile-based categories
Good controlled, N (%) (referent) 142 (23.3) 13 (2.1) 140 (23.0) 15 (2.5) 94 (15.4) 61 (10.0)
Moderately controlled, N (%) 141 (23.2) 10 (1.6) 138 (22.7) 13 (2.1) 81 (13.3) 70 (11.5)
Unadjusted odds 1.0 0.77 (0.33–1.82) 1.0 0.90 (0.40–1.92) 1.0 1.33 (0.85–2.10)
Adjusted odds 1.0 0.90 (0.28–2.91) 1.0 0.95 (0.32–2.82) 1.0 1.29 (0.77–2.16)
Poorly controlled, N (%) 135 (22.2) 15 (2.5) 137 (22.5) 13 (2.1) 80 (13.1) 70 (11.5)
Unadjusted odds 1.0 1.21 (0.57–2.64) 1.0 0.89 (0.41–1.93) 1.0 1.35 (0.86–2.12)
Adjusted odds 1.0 1.59 (0.52–4.87) 1.0 0.58 (0.20–1.79) 1.0 1.24 (0.74–2.10)
Very poorly controlled, N (%) 139 (22.8) 14 (2.3) 141 (23.2) 12 (2.0) 68 (11.2) 85 (14.0)
Unadjusted odds 1.0 1.10 (0.50–2.42) 1.0 0.79 (0.36–1.76) 1.0 1.93 (1.22–3.03)a
Adjusted odds 1.0 1.43 (0.45–4.55) 1.0 0.47 (0.15–1.49) 1.0 1.70 (1.01–2.88)a
Odds ratio adjusted for depression or anxiety, age, comorbidities, physical activity, BMI, and physical health. Classificationmethod usedwas logistic and
multinomial regression
a Statistically significant
Table 4 Odds ratio (95 % CI) of fasting glucose level according to depression and anxiety symptoms (n=352)
Items Depression symptoms Anxiety symptoms Mental health—MCS
No (referent) Yes No (referent) Yes Good MCS (referent) Poor MCS
FBG—categories
Normal level, N (%) (referent) 75 (21.3) 5 (1.3) 75 (21.3) 5 (1.3) 43 (12.2) 37 (10.5)
Moderate level, N (%) 52 (14.8) 6 (1.7) 49 (13.9) 9 (2.6) 33 (9.4) 25 (7.1)
Unadjusted odds 1.0 1.73 (0.50–5.97) 1.0 2.75 (0.87–8.71) 1.0 0.88 (0.44–1.74)
Adjusted odds 1.0 0.88 (0.17–4.58) 1.0 3.38 (0.67–17.11) 1.0 0.81 (0.33–1.74)
High level, N (%) 194 (55.1) 18 (5.1) 197 (56.0) 13 (3.7) 97 (27.6) 117 (33.2)
Unadjusted odds 1.0 1.55 (0.56–4.27) 1.0 1.29 (0.46–3.63) 1.0 1.40 (0.84–2.35)
Adjusted odds 1.0 1.47 (0.41–5.26) 1.0 0.92 (0.23–3.61) 1.0 1.18 (0.60–2.34)
Fasting glucose adjusted for depression or anxiety, age, comorbidities, physical activity, BMI, physical health, and sleep problems. Classification method
used was logistic and multinomial regression
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Limitations
Our assessment of depression and anxiety symptoms was
based on self-report of symptoms using validated instruments
and not on the Diagnosis and Statistical Manual (DSM)
criteria based clinical diagnostic interview. A clinical confir-
mation of depression or anxiety could not be done because the
DSM for diagnosis of mental disorders states that the standard
diagnostic criteria are applied “in the presence of a psychiatrist
or trained healthcare professional.” Therefore, two instru-
ments were used to examine depression or anxiety symptoms
as no clinical confirmation was available. Although we ap-
plied systematic sampling, participants who frequently
attended the outpatient clinics were more likely to be sampled
than those who attended less frequently, and therefore were
presumed to have better glycemic control. This might have
introduced selection bias.
Conclusions
This study did not find significant associations between
depression and glycemic control and anxiety and glyce-
mic control in Malaysian women with T2DM. Despite
strong inverse correlations of MCS with DSSI-Anxiety
and CES-D 10, only MCS tended to be associated with
significant changes in glycemic control in this study.
This evidence supports the hypothesis that argues
against the existence of a link between depression and
glycemic control and anxiety and glycemic control.
However, as primary care physicians may fail to recog-
nize a substantial number of patients with depression
and/or anxiety symptoms and as the prevalence of dia-
betes continues to increase, in Malaysia, it is important
for health care professionals managing patients with DM
to be aware of the association between depression,
anxiety symptoms, and glycemic control to prevent fur-
ther complications.
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